Clinical study of Lamotrigine combined with Escitalopram Oxalate in the treatment of post-stroke epilepsy comorbid depression patients
ZHANG Shanshan JI Yifei ZHANG Yi QU Zhanli ZHOU Huayong
Department of Neurology, the Second Clinical Medical College of North Sichuan Medical College Nanchong Central Hospital, Sichuan Province, Nanchong 637000, China
Abstract：Objective To explore the clinical effects of Lamotrigine combined with Escitalopram Oxalate in the treatment of post-stroke epilepsy comorbid depression patients. Methods From January 2015 to August 2018, 126 cases of patients with post-stroke epilepsy comorbid depression treated in Nanchong Central Hospital of Sichuan Province were selected as research objects and divided into the control group and the observation group by the method of randomized digital table, with 63 cases in each group. The control group was treated with Lamotrigine, and the observation group was given Lamotrigine combined with Escitalopram Oxalate, for 3 months of treatment. The frequency of seizures, adverse drug reactions, Hamilton depression scale (HAMD), National Institutes of Health Stroke scale (NIHSS), Barthel index (BI) and MMSE scores were compared between the two groups. Results After treatment, the seizure frequency, HAMD and NIHSS scores in the observation group were significantly lower than those before treatment, and lower than the control group (P ＜ 0.05). The MMSE score and BI were significantly higher than those before treatment (P ＜ 0.05), and significantly higher than the control group (P ＜ 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Lamotrigine combined with Escitalopram Oxalate can not only improve the depressive symptoms, the cognitive function, the neurological function and the quality of life of post-stroke epilepsy comorbid depression patients, but also does not increase the risk of recurrence of epilepsy and has high safety.
[1] Hasan TF，Rabinstein AA，Middlebrooks EH，et al. Diagnosis and management of acute ischemic stroke [J]. Mayo Clin Proc，2018，93：523-538.
[2] Pande SD，Lwin MT，Kyaw KM，et al. Post-stroke seizure-Do the locations，types and managements of stroke matter? [J]. Epilepsia Open，2018，3（3）：392-398.
[3] Shu HW，Lin M，Zhao YS，et al. Analysis of depression and anxiety in patients with post-stroke epilepsy [J]. Int J Clin Exp Med，2017，10（4）：6994-6999.
[4] Mitchell AJ，Sheth B，Gill J，et al. Prevalence and predictors of post-stoke mood disorders：A meta-analysis and metaregression of depression，anxiety and adjustement disorder [J]. Gen Hosp Psychiatry，2017，47：48-60.
[5] Feyissa AM，Hasan TF，Meschia JF. Stroke-related epilepsy [J]. Eur J Neurol，2019，26（1）：18-e3.
[6] 秦兵，吴逊，徐纪文，等.2014 年国际抗癫痫联盟癫痫新定义会议[J].中华医学杂志，2014，94（28）：2161-2164.
[7] 中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版（精神障碍分类）[J].中华精神科杂志，2001，34（3）：84-188.
[8] 张明园.精神科评定量表手册[M].2版.长沙：湖南科学技术出版社，1998：121-126.
[9] Yoshimura S，Lindley RI，Carcel C，et al. NIHSS cut point for predicting outcome in supra- vs infratentorial acute ischemic stroke [J]. Neurology，2018，91（18）：e1695-e1701.
[10] Prodinger B，O'Connor RJ，Stucki G，et al. Establishing score equivalence of the Functional Independence Measure motor scale and the Barthel Index，utilising the International Classification of Functioning，Disability and Health and Rasch measurement theory [J]. J Rehabil Med，2017，49（5）：416-422.
[11] Tombaugh TN，Mclntyre NJ. The minimental state examination：a comprehensive review [J]. J Am Geriatr Soc，1992，40（9）：922-935.
[12] 刘增雪，陆静珏，周一心.关于卒中后抑郁发病机制的研究新进展[J].中国医药导报，2019，16（2）：24-28.
[13] Ferrari F，Villa RF. The neurobiology of depression：an integrated overview from biological theories to clinical evidence [J]. Mol Neurobiol，2017，54（7）：4847-4865.
[14] 郭旭，彭春，游俊杰，等.脑卒中后抑郁大鼠海马BDNF及其受体 TrkB 蛋白的表达变化[J].神经解剖学杂志，2014，30（1）：19-22.
[15] Xu JH，Jiang P. Efficacy of escitalopram oxalate for patients with post-stroke depression [J]. Medicine，2018，97（14）：e0219.
[16] Steinert T，Fr?觟scher W. Epileptic Seizures Under Antidepressive Drug Treatment：Systematic Review[J]. Pharmacopsychiatry，2018，51（4）：121-135.
[17] Payandemehr B，Ghasemi M，Dehpour AR. Citalopram as a good candidate for treatment of depression in patients with epilepsy [J]. Epilepsy Behav，2015，44：96-97.
[18] Conrad J，Pawlowski M，Dogan M，et al. Seizures after cerebrovascular events：risk factors and clinical features [J]. Seizure，2013，22（4）：275-282.
[19] Espinera AR，Ogle ME，Gu X，et al. Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice [J]. Neuroscience，2013，247：1-11.
[20] 黄敏芳，刘纪猛，刘灵江，等.文拉法辛和艾司西酞普兰治疗抑郁症的效果及对心率变异性和自主神经功能的影响比较[J].中国医药导报，2018，15（16）：130-133.
[21] Gupta S，Upadhayay D，Sharma U，et al. Citalopram attenuated neurobehavioral，biochemical，and metabolic alterations in transient middle cerebral artery occlusion model of stroke in male Wistar rats [J]. J Neurosci Res，2018，96（7）：1277-1293.
[22] 陈泳康，李洋，李镔.西酞普兰辅助重复经颅磁刺激对成人首发抑郁症患者HAMD评分、生活质量及不良反应的影响[J].中国医药科学，2018，8（15）：210-212，250.
[23] 范雪云.艾司西酞普兰合并电针对老年抑郁症的临床疗效及生活质量分析[J].中国现代医生，2018，56（2）：77-79.
2019, Vol. 16 
京公网安备 11010502046598号